利培酮及奋乃静治疗青少年精神分裂症对照探究.docVIP

利培酮及奋乃静治疗青少年精神分裂症对照探究 　【摘要】 目的 探讨利培酮治疗青少年精神分裂症的临床疗效及安全性。 方法 将65例青少年精神分裂症患者随机分为两组，研究组34例，口服利培酮治疗，对照组31例，口服奋乃静治疗。观察8 w。于治疗前及治疗8 w末采用阳性与阴性症状量表评定临床疗效、副反应量表评定不良反应。 结果 治疗8 w末，研究组显效率82.3%，对照组为80.6%，两组显效率比较无显著性差异（Pgt;0.05）；两组治疗8 w末阳性与阴性症状量表总分及各因子分均较治疗前下降明显（P均＜0.01），同期两组间比较均无显著性差异（P均＞0.05）；研究组肌肉震颤、静坐不能、口干、心动过速等不良反应发生率均显著低于对照组（P＜0.05）。 结论 利培酮治疗青少年精神分裂症疗效显著，不良反应轻，安全性高，依从性好。 【关键词】 青少年精神分裂症；奋乃静；利培酮；阳性与阴性症状量表；副反应量表 【Abstract】 Objective To explore the clinical effeicacy and safety of riperidone in adolescent schizophrenia. Methods Sixtyfive adolescent schizophrenics were randomly divided into research group(n=34) taking orally riperidone and control group(n=31) doing chlorpiprazine for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale(PANSS) and adverse reactions with the Treatment Emergent Symptom Scale(TESS) before and after treatment.Results At the end of the 8th week, obviously effective rates were 82.3% in the research and 80.6% in the control group, which showed no significant difference(Pgt;0.05);total and each factor score of the PANSS of both groups lowered more significantly compared with pretreatment(both Plt;0.01), there were no significant differences in synchronization intergroup comparisons between the 2 groups(all Pgt;0.05); incidences of adverse reactions such as moscle tremor, akathisia, dry mouth, tachycardia etc. were significantly lower in the research than in the control group(Plt;0.05).Conclusion Riperidone has an evident effect,mild adverse reactions,higher safety and better compliance in the treatment of adolescent schizophrenia. 【Keywords】 Adolescent scizophrenia; chlorpiprazine;risperidone;PANSS;TESS 利培酮是一种新型非典型抗精神病药，对精神分裂症阴性、阳性症状均有良好的疗效，患者服药耐受性和依从性均较好［1］。为探讨利培酮治疗青少年精神分裂症的临床疗效及安全性，我们与奋乃静进行了对照研究，现报道如下。 1 对象与方法 1.1 对象 选取2004年5月～2006年11月在我院住院治疗的青少年精神分裂症患者为研究对象。入组标准：（1）符合《中国精神障碍分类与诊断标准》第3版（CCMD3）青少年精神分裂症诊断标准。（2）年龄15 a～18 a。（3）排除其它躯体疾病和脑器质性疾病。共入组65例，随机分为两组。研究组34例，男21例，女13例；平均年龄（17.2±1.5） a，平均病程（1.0±0.3） a。对照组31例，